[1]袁卫红,张怡,罗志航.内分泌性眼病患者外周血中白细胞介素6和胰岛素样生长因子1水平变化的研究[J].国际放射医学核医学杂志,2008,32(3):167-169.
　YUAN Wei-hong,ZHANG Yi,LUO Zhi-hang.The investigation of cytokine level in peripheral blood of patients with thyroid eye disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2008,32(3):167-169.
点击复制

内分泌性眼病患者外周血中白细胞介素6和胰岛素样生长因子1水平变化的研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
32
期数:
2008年第3期
页码:
167-169
栏目:
临床核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The investigation of cytokine level in peripheral blood of patients with thyroid eye disease
作者:
袁卫红;  张怡;  罗志航
650101 昆明, 昆明医学院第二附属医院核医学科
Author(s):
YUAN Wei-hong;  ZHANG Yi;  LUO Zhi-hang
Department of Nuclear Medicine, The Second Affiliated Hospital, Kunming Medicine College, Kunming 650101, China
关键词:
格雷夫斯病; 甲状腺功能亢进症; 白细胞介素6; 胰岛素样生长因子1
Keywords:
Graves disease; Hyperthyroidism; Interleukin-6; Insulin-like growth factor-1
摘要:
目的 测定内分泌性眼病患者外周血中的细胞因子,包括血清白细胞介素6(IL-6),胰岛素样生长因子1(IGF-1)的水平变化,寻找IL-6及IGF-1与内分泌性眼病的发病情况以及病情变化的关系。方法 30例内分泌性眼病患者、30例无突眼甲亢患者、健康对照组30例,用放射免疫分析法分别对以上3组患者人血清IL-6、IGF-1进行测定。结果 内分泌性眼病组患者血清IL-6、IGF-1的水平较无突眼的甲亢组(t=4.20、t=4.00,P<0.01)和健康对照组0=420、t=4.05,P<0.01)显著升高,而且IL-6、IGF-1的水平变化随内分泌性眼病患者眼病的分级程度增加而升高,均有显著性差异。结论 外周血中IL-6、IGF-1水平与内分泌性眼病的发病密切相关,而且IL-6、IGF-1的水平与内分泌性眼病的严重程度呈正相关。
Abstract:
Objective To detect the level of serum interleukin-6(IL-6)and insulin-lide growth factor-1(IGF-1)in patients with thyroid eye disease and to seek the rehtionship between serum level and the outbreak as well as the condition variety.Methods To measure the level of serumm IL-6 and IGF-1 by radioimmunoassay in 30 patients with thyroid eye disease after their clinical expression and activity Score have been assessed,30 patients with hyperthyroidism but without ophthalmopathy,30 healthy subjects.Results The level of serum IL-6 and IGF-1 in patients with thyroid eye disease were higher than that of patients with hyperthyroidism but without ophthalmopathy(t-4.20、t-4.00,P<0.01)and healthy subjects (t-4.20、t-4.05,P<0.01).IL-6 andIGF-1 levels tend to elevate With the increase of severity of eye disease.There were significant differedces among them.Conclusion The leve of IL-6,IGF-1 and the Cause of thyroid eye disease are closely related,and IL-6 and IGF-1 levels in peripheral blood might reflect the severity ofeye disease.

参考文献/References:

[1] 宋国祥.眼眶病的发病率[M].李凤鸣,主编.眼科全书.上册.北京:人民卫生出版社,1996.1100-1130.
[2] Hiromatsu Y, Yang D, Bednarczuk T, et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroidassociated ophthalmopathy[J]. J Clin Endocrinol Metab, 2000, 85(3):1194-1199.
[3] 腾卫平,曾正陪,李光伟,等.中国甲状腺疾病诊治指南[G].地点中华医学会内分泌学学会汇编,2005.24-25.
[4] 赵同涛, 刘翔.甲状腺相关眼病研究进展[J].重庆医学,2005,34(10):1547-1549.
[5] Kumar S, Bahn RS. Relative overexpression of macrophagederived cytokines in orbital adipose tissue from patients with graves’ ophthalmopathy[J]. J Clin Endocrinol Metab, 2003, 88(9):4246-4250.
[6] Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of ordiotherapy versus sham irradiation in patients with mild Graves, ophthalmopat h[J]. J Clin Endocrinol Metab, 2004, 89(1):15-20.
[7] EI-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy:a practical guide to classication, natural history and management[J]. Intern Med J, 2004, 34(8):482-491.
[8] Kaspar M, Archibald C, De BA, et al. Eye muscle antibodies and subtype of thyroid-associated ophthalmopathy[J]. Thyroid, 2002, 12(3):187-191.
[9] Cauwood T, Moriarty P, O’Shea D. Recent development in thyroid eye disease[J]. BMJ, 2004, 329(7462):385-390.

相似文献/References:

[1]杨宝军.131I治疗甲亢合并特发性血小板减少性紫癜一例[J].国际放射医学核医学杂志,2015,39(6):511.[doi:10.3760/cma.j.issn.1673-4114.2015.06.017]
[2]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[3]胡小春,蒋宁一,李敬彦,等.硒对经131I治疗Graves病患者血清甲状腺过氧化物酶抗体水平的影响[J].国际放射医学核医学杂志,2015,39(2):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
　Hu Xiaochun,Jiang Ningyi,Li Jingyan,et al.Effect of additional selenium on the levels of serum thyroid peroxidase antibody in patients with Graves disease treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):140.[doi:10.3760/cma.j.issn.1673-4114.2015.02.008]
[4]查金顺,蒋艳,徐源,等.131I辅以短期小剂量碳酸锂治疗Graves甲亢的研究[J].国际放射医学核医学杂志,2014,38(1):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
　Zha Jinshun,Jiang Yah,Xu Yuan,et al.Clinical research on radioiodine addition of low-doses of lithium carbonate in short-term treatment of Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):10.[doi:10.3760/cma.j.issn 1673-4114.2014.01.003]
[5]俞秀华,黄炜坤,林玉梅.131I治疗Graves病合并肝损害的临床观察[J].国际放射医学核医学杂志,2014,38(2):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
　Yu Xiuhua,Huang Weikun,Lin Yumei.Clinical observation of 131I therapy in Graves disease patients with hepatic dysfunction[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):90.[doi:10.3760/cma.j.issn.1673-4114.2014.02.005]
[6]王深,孟召伟,贾强,等.MRI弥散加权成像、甲状腺摄碘率和血清指标测定鉴别Graves甲状腺功能亢进症和无痛性甲状腺炎的研究[J].国际放射医学核医学杂志,2014,38(6):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
　Wang Shen,Meng Zhao-wei,Jia Qiang,et al.Differentiation between Graves disease and painless thyroiditis by diffusion-weighted imaging, thyroid radioactive iodine uptake and serum parameters measurement[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(3):392.[doi:10.3760/cma.j.issn.1673-4114.2014.06.011]
[7]郑艳,赵德善,付松海,等.儿童和青少年Graves甲亢患者131Ⅰ治疗剂量的分析研究[J].国际放射医学核医学杂志,2013,37(2):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
　ZHENG Yan,ZHAO De-shan,FU Song-hai,et al.The dose analysis of 131Ⅰ treatment in pediatric patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):69.[doi:10.3760/cma.j.issn.1673-4114.2013.02.002]
[8]王朝点,史育红,颜兵.TRAb水平测定在Graves眼病中的临床意义探讨[J].国际放射医学核医学杂志,2013,37(2):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
　WANG Chao-dian,SHI Yu-hong,YAN Bing.The clinical value of serum thyrotrophin receptor antibody level in patients with Graves ophthalmopathy[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):77.[doi:10.3760/cma.j.issn.1673-4114.2013.02.004]
[9]张建媛,缪蔚冰.电化学发光法与放射性受体分析法检测促甲状腺激素受体抗体的对比研究[J].国际放射医学核医学杂志,2012,36(1):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
　ZHANG Jian-yuan,MIAO Wei-bing.Comparative study between electrochemiluminescence immunoassay and radioactive receptor assay in measurement of serum thyrotropin receptor antibody[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):20.[doi:10.3760/cma.j.issn.1673-4114.2012.01.005]
[10]黄春玲,查金顺,蒋婷吟.甲状腺功能亢进症患者血浆中TNF-α1和IL-2水平的临床分析[J].国际放射医学核医学杂志,2012,36(2):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
　HUANG Chunling,ZHA Jin-shun,JIANG Ting-yin.The clinical analysis of the TNF-α1 and IL-2 levels in patients with hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(3):92.[doi:10.3760/cma.j.issn.1673-4114.2012.02.008]
[11]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[12]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(3):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[13]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[14]张丽花,蒋宁一.131I治疗Graves甲亢合并肝功能损害或血细胞减少的优势与风险[J].国际放射医学核医学杂志,2015,39(6):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
　Zhang Lihua,Jiang Ningyi.The advantage and risk of 131I treatment in hyperthyroidism combined with liver injury or blood cell reduction[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(3):483.[doi:10.3760/cma.j.issn.1673-4114.2015.06.010]
[15]张瑞国,秦岚,张又萍,等.初诊Graves甲亢合并肝损害及其影响因素的临床分析[J].国际放射医学核医学杂志,2013,37(5):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
　ZHANG Rui-guo,QIN Lan,ZHANG You-ping,et al.Clinical study of hepatic dysfunction and its correlative factors in newly diagnosed patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2013,37(3):283.[doi:10.3760/cma.j.issn.1673-4114.2013.05.008]
[16]孙琦婷,赵德善.Graves病甲状腺功能亢进症与血糖代谢[J].国际放射医学核医学杂志,2010,34(3):143.
　SUN Qi-ting,ZHAO De-shan.Graves disease hyperthyroidism and glycometabolism[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(3):143.
[17]覃伟武.131Ⅰ治疗非Graves’甲状腺功能亢进及非毒性甲状腺肿后诱发Graves’病[J].国际放射医学核医学杂志,2006,30(6):325.
　QIN Wei-wu.Induction of Graves’ disease in patients with non-autoimmune hyperthyroidism or nontoxic goiter after radioiodine treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2006,30(3):325.
[18]赵炎,王俊起,沈婕.Graves病的131I治疗和抗甲状腺药物治疗:随机对照试验荟萃分析[J].国际放射医学核医学杂志,2017,41(6):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]
　Zhao Yan,Wang Junqi,Shen Jie.131I therapy versus antithyroid drugs in Graves’ disease:a meta-analysis of randomized controlled trials[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(3):389.[doi:10.3760/cma.j.issn.1673-4114.2017.06.003]

备注/Memo

备注/Memo:
收稿日期:2007-11-05。
通讯作者:袁卫红(E-mail:yuantianhe@163.com)
更新日期/Last Update: 1900-01-01